Company intelligence / Profile preview
Shanxi Xinbaoyuan Pharmaceutical
- Ownership
- Private
- Development stage
- Other
Overview
Shanxi Xinbaoyuan Pharmaceutical has at least one approved drug product—bismuth pectin—for the treatment of chronic superficial gastritis. The company specializes in the production of bulk drugs and APIs including local anesthetics and antitussives, as well as digestive system agents. It operates a full industry chain from pharmaceutical intermediates to finished formulations. No clinical trial data or results are publicly detailed.
- Therapeutic areas
- Gastroenterology
- Modalities
- Small molecule
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Shanxi Xinbaoyuan Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanxi Xinbaoyuan Pharmaceutical.